Less than 10% of people that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it releases its inaugural guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a long-term condition that can be treated with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are key hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, says the body.
Weight-Loss Drug Scarcity
Even under the present most optimistic outlook, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline calls on nations and manufacturers to expand access, through measures such as patent sharing.
Exclusive production rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Drugs Function
The injections imitate a natural hormone to delay gastric emptying, curb appetite and increase satiety so users consume fewer calories.
Individuals usually begin shedding pounds within a few weeks of starting on the regular doses.
Studies points to people may put most of the weight back on a year later of discontinuing the treatment, as their usual appetite come back.
To be above a healthy weight raises your likelihood for developing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
